Breaking Through the Noise: Building Marketable AI Platforms in Biotech

Artificial intelligence (AI) has become a widely used label across biotech companies positioning platforms for drug discovery and development. However, what truly defines an AI-marketed platform today goes beyond the presence of advanced algorithms or biological claims. As the industry enters 2026, the central challenge is no longer whether AI can support innovation, but which AI platforms can demonstrate clear return on investment, commercial credibility, and scalability as services for biomedical development that customers are willing to pay for. This session will bring together AI-biotech founders, AI economics experts, and investors to examine what distinguishes successful AI platforms that are marketed and adopted as revenue-generating services rather than as internal programs. Panelists will explore the attributes that enable AI platforms to move from pilot studies to repeat customers, including validation of real-world performance, integration into existing R&D and clinical workflows, applicability across therapeutic and diagnostic areas, and the ability to deliver measurable economic value to pharma, biotech, and healthcare providers.